Blood and lymphatic system disorders – page 38

Study of isatuximab, evorpacept and dexamethasone combination therapy for patients with relapsed or refractory multiple myeloma

Study of isatuximab, evorpacept and dexamethasone combination therapy for patients with relapsed or refractory multiple myeloma

Study on Tioguanine and Drug Combination for Patients Aged 0-45 with Newly Diagnosed Acute Lymphoblastic Leukemia

Study on Tioguanine and Drug Combination for Patients Aged 0-45 with Newly Diagnosed Acute Lymphoblastic Leukemia

Study on Decitabine, Venetoclax, and Tretinoin for Patients with Acute Myeloid Leukemia Who Cannot Have Induction Chemotherapy

Study on Decitabine, Venetoclax, and Tretinoin for Patients with Acute Myeloid Leukemia Who Cannot Have Induction Chemotherapy

Study on Luspatercept and Epoetin Alfa for Patients with Low-Risk Myelodysplastic Syndrome Without Ring Sideroblasts Who Did Not Respond to ESA

Study on Long-Term Safety and Effects of Iptacopan for Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

Study on Long-Term Safety and Effects of Iptacopan for Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

Study on Tasquinimod for Patients with Myelofibrosis Who Are Refractory or Intolerant to JAK2 Inhibitors

Study on Tasquinimod for Patients with Myelofibrosis Who Are Refractory or Intolerant to JAK2 Inhibitors

Study on Hydroxychloroquine for Patients with Cutaneous Mastocytosis or Indolent Systemic Mastocytosis with Skin Involvement

Study on Hydroxychloroquine for Patients with Cutaneous Mastocytosis or Indolent Systemic Mastocytosis with Skin Involvement

Study Comparing Venetoclax and Azacitidine with Standard Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia Patients with NPM1 Mutations Eligible for Intensive Treatment

Study Comparing Venetoclax and Azacitidine with Standard Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia Patients with NPM1 Mutations Eligible for Intensive Treatment

Study on Blinatumomab, Ponatinib, and Isatuximab for Adults Aged 18-65 with Newly Diagnosed Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma

Study on Blinatumomab, Ponatinib, and Isatuximab for Adults Aged 18-65 with Newly Diagnosed Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma

Study of MEN1703 and Glofitamab for Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Study of MEN1703 and Glofitamab for Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Study of Dasatinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with MAPK/SRC Pathway Mutation

Study of Dasatinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with MAPK/SRC Pathway Mutation

Study comparing venetoclax with intensive chemotherapy (daunorubicin, cytarabine, gemtuzumab ozogamicin) in patients with favorable risk acute myeloid leukemia

Study comparing venetoclax with intensive chemotherapy (daunorubicin, cytarabine, gemtuzumab ozogamicin) in patients with favorable risk acute myeloid leukemia